相关临床试验
190
41 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1971
进行中（未招募）
8
4.2%
已完成
94
49.5%
尚未招募
33
17.4%
招募中
41
21.6%
终止
7
3.7%
撤回
7
3.7%
暂无批准数据
- Analysis of two ancient skeletons from Sulawesi, Indonesia, found traces of the psychoactive compound arecoline in teeth, dating human drug use back as far as 25,000 years. - The individuals show distinctive tooth grooves consistent with repeatedly sucking on betel nuts, predating the oldest known drug-use evidence by at least 3,000 years. - Researchers confirmed the mechanism experimentally by soaking betel nuts in artificial saliva and testing the extract on frog egg cells engineered with human brain receptors. - The findings suggest betel nut sucking may have served as a painkiller, creating a self-perpetuating cycle of tooth damage and addiction.
- Griffith University researchers announced successful Phase II trial results for STC3141, a carbohydrate-based drug candidate targeting sepsis, one of the leading causes of death globally. - The small-molecule experimental drug, administered via infusion, met key endpoints by successfully reducing sepsis in humans and works by counteracting harmful biological molecule release during sepsis. - Currently no specific anti-sepsis therapy exists, representing a significant clinical unmet need as sepsis affects millions of hospitalized patients annually through immune system attacks on body tissues. - Grand Pharmaceutical Group Limited conducted the trial, which now paves the way for Phase III testing with potential market availability within a few years.
- The US FDA has granted fast track designation to Sanofi's mRNA vaccine candidate for chlamydia prevention, recognizing its potential to address a serious unmet public health need. - The vaccine aims to protect against primary genital tract infection and reinfection by Chlamydia trachomatis, with a Phase 1/2 clinical trial in adults aged 18-29 set to begin imminently. - With 129 million global chlamydia cases reported in 2020 and over 80% being asymptomatic, the vaccine could transform prevention efforts where current antibiotic treatments have failed to control rising infection rates.
- A Phase I clinical trial has commenced to evaluate the safety and efficacy of transplanting olfactory ensheathing cell nerve bridges for chronic spinal cord injury. - The trial utilizes nerve bridges made from the patient's own purified nasal cells, combined with intensive rehabilitation, to encourage nerve regeneration at the injury site. - This approach addresses technical limitations of previous cell transplantation trials by using innovative nerve bridges and high-purity olfactory cells. - The study seeks volunteers with chronic spinal cord injuries and is funded by various organizations, including the Medical Research Future Fund and the Perry Cross Spinal Research Foundation.
